Los Angeles Capital Management
EWTX icon

Los Angeles Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Los Angeles Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Sell
5,600
-2,577
-32% -$74.3K ﹤0.01% 1179
2025
Q4 		$153K Buy
+8,177
New +$164K ﹤0.01% 1314

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Los Angeles Capital Management's EWTX Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 32% in Q1 2026, selling an estimated $74.3K and leaving 5,600 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #1179.

Los Angeles Capital Management first reported a position in EWTX in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Los Angeles Capital Management held 5,600 shares of Edgewise Therapeutics worth $176K as of Q1 2026.
  • Los Angeles Capital Management sold 2,577 Edgewise Therapeutics shares in Q1 2026, an estimated $74.3K.
  • Edgewise Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1179 holding.
  • Los Angeles Capital Management first reported a position in Edgewise Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.